Michael Marber

Dr. Michael Marber

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2017 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
KPKyung Chan Park
Kyung Chan Park
DGDavid C Gaze
David C Gaze
PCPaul O Collinson
Paul O Collinson
MMMichael Marber
Michael Marber
Elucidation of the physiologically distinct subunits of troponin in 1973 greatly facilitated our understanding of cardiac contraction. Although troponins are expressed in both skeletal and cardiac muscle, there are isoforms of troponin I/T expressed selectively in the heart. By exploiting cardiac-restricted epitopes within these proteins, one of the most successful diagnostic tests to date has been developed: cardiac troponin (cTn) assays. For the past decade, cTn has been regarded as the gold-standard marker for acute myocardial necrosis: the pathological hallmark of acute myocardial infarction (AMI). Whilst cTn is the cornerstone for ruling-out AMI in patients presenting with a suspected acute coronary syndrome (ACS), elevated cTn is frequently observed in those without clinical signs indicative of AMI, often reflecting myocardial injury of ‘unknown origin’. cTn is commonly elevated in acute non-ACS conditions, as well as in chronic diseases. It is unclear why these elevations occur; yet they cannot be ignored as cTn levels in chronically unwell patients are directly correlated to prognosis. Paradoxically, improvements in assay sensitivity have meant more differential diagnoses have to be considered due to decreased specificity, since cTn is now more easily detected in these non-ACS conditions. It is important to be aware cTn is highly specific for myocardial injury, which could be attributable to a myriad of underlying causes, emphasizing the notion that cTn is an organ-specific, not disease-specific biomarker. Furthermore, the ability to detect increased cTn using high-sensitivity assays following extreme exercise is disconcerting. It has been suggested troponin release can occur without cardiomyocyte necrosis, contradicting conventional dogma, emphasizing a need to understand the mechanisms of such release. This review discusses basic troponin biology, the physiology behind its detection in serum, its use in the diagnosis of AMI, and some key concepts and experimental evidence as to why cTn can be elevated in chronic diseases.

20 June 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
ENEike Nagel
Eike Nagel
JGJohn P. Greenwood
John P. Greenwood
GMGerry P. McCann
Gerry P. McCann
NBNuno Bettencourt
Nuno Bettencourt
ASAjay M. Shah
Ajay M. Shah
CBColin Berry
Colin Berry
In patients with stable angina, two strategies are often used to guide revascularization: one involves myocardial-perfusion cardiovascular magnetic resonance imaging (MRI), and the other involves invasive angiography and measurement of fractional flow reserve (FFR). Whether a cardiovascular MRI–based strategy is noninferior to an FFR-based strategy with respect to major adverse cardiac events has not been established.

28 April 2004 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DHDavid G. Hay
David G. Hay
KSKirupa Sathasivam
Kirupa Sathasivam
STSönke Tobaben
Sönke Tobaben
BSBernd Stahl
Bernd Stahl
MMMichael Marber
Michael Marber
GBGillian P. Bates
Gillian P. Bates
The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a progressive decrease in Hdj1, Hdj2, Hsp70, αSGT and βSGT brain levels likely contributes to disease pathogenesis in the R6/2 mouse model of HD. Despite a predominantly extranuclear location, Hdj1, Hdj2, Hsc70, αSGT and βSGT were found to co-localize with nuclear but not with extranuclear aggregates. Quantification of Hdj1 and αSGT mRNA levels showed that these do not change and therefore the decrease in protein levels may be a consequence of their sequestration to aggregates, or an increase in protein turnover, possibly as a consequence of their relocation to the nucleus. We have used genetic and pharmacological approaches to assess the therapeutic potential of chaperone manipulation. Ubiquitous overexpression of Hsp70 in the R6/2 mouse (as a result of crossing to Hsp70 transgenics) delays aggregate formation by 1 week, has no effect on the detergent solubility of aggregates and does not alter the course of the neurological phenotype. We used an organotypic slice culture assay to show that pharmacological induction of the heat shock response might be a more useful approach. Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course.

20 October 2016 in Basic Research in Cardiology
Verified
Journal Article
Open access
PDF file
DHDerek Hausenloy
Derek Hausenloy
José BarrabésJosé Barrabés
José Barrabés
HBHans Erik Bøtker
Hans Erik Bøtker
SDSean M. Davidson
Sean M. Davidson
FLFabio Di Lisa
Fabio Di Lisa
DGDavid Garcia-Dorado
David Garcia-Dorado
To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.

1 February 2008 in Hypertension
Verified
Journal Article
Closed access
YLYee H. Looi
Yee H. Looi
DGDavid J. Grieve
David J. Grieve
ASAnjana Siva
Anjana Siva
SWSimon J. Walker
Simon J. Walker
NANarayana Anilkumar
Narayana Anilkumar
ASAjay M Shah
Ajay M Shah
Oxidative stress plays an important role in the development of cardiac remodeling after myocardial infarction (MI), but the sources of oxidative stress remain unclear. We investigated the role of Nox2-containing reduced nicotinamide-adenine dinucleotide phosphate oxidase in the development of cardiac remodeling after MI. Adult Nox2 −/− and matched wild-type (WT) mice were subjected to coronary artery ligation and studied 4 weeks later. Infarct size after MI was similar in Nox2 −/− and WT mice. Nox2 −/− mice exhibited significantly less left ventricular (LV) cavity dilatation and dysfunction after MI than WT mice (eg, echocardiographic LV end-diastolic volume: 75.7±5.8 versus 112.4±12.3 μL; ejection fraction: 41.6±3.7 versus 32.9±3.2%; both P <0.05). Similarly, in vivo LV systolic and diastolic functions were better preserved in Nox2 −/− than WT mice (eg, LV dP/dt max : 7969±385 versus 5746±234 mm Hg/s; LV end-diastolic pressure: 12.2±1.3 versus 18.0±1.8 mm Hg; both P <0.05). Nox2 −/− mice exhibited less cardiomyocyte hypertrophy, apoptosis, and interstitial fibrosis; reduced increases in expression of connective tissue growth factor and procollagen 1 mRNA; and smaller increases in myocardial matrix metalloproteinase–2 activity than WT mice. These data suggest that the Nox2-containing reduced nicotinamide-adenine dinucleotide phosphate oxidase contributes significantly to the processes underlying adverse cardiac remodeling and contractile dysfunction post-MI.